Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.
?In this Phase I study, we are examining the safety of multiple doses of dexanabinol, extent of penetration into the brain, and suitability for future trials,? said Santosh Kesari, MD, PhD, principal investigator, and director of neuro-oncology, UC San Diego Moores Cancer Center. ?What we hope to determine is the safe and optimal dose of drug in the brain.?
Dexanabinol is a cannabinoid derivative that causes no psychotropic effects. It was tested previously as a neuroprotective in patients with traumatic brain injury. During these trials the drug was found to cross the blood-brain barrier. More recently, researchers at e-Therapeutics, the trial sponsor, showed that dexanabinol kills cultured cancer cells derived from many tumor types. Additional research in Kesari?s lab demonstrated the drug?s anti-cancer effects in patient-derived brain cancer cell lines.
Dexanabinol?s potential in fighting cancer was identified through a new approach to drug discovery called network pharmacology, a way to analyze the network of proteins underlying a disease process. Network pharmacology enables scientists to seek drugs from among existing compounds, or design new molecules, that act simultaneously on a number of individual proteins to disrupt the cancer-susceptible network.
Article source: http://www.news-medical.net/news/20120926/UCSD-evaluates-safety-and-tolerability-of-dexanabinol-in-Phase-I-brain-cancer-study.aspx
boston globe google maps 8 bit mirror mirror robyn texas relays meniscus the colony
No comments:
Post a Comment